Core Points - SciSparc Ltd. has been granted an additional 180-day compliance period by Nasdaq to regain compliance with the minimum bid price rule, extending the deadline to July 14, 2025 [1][3] - The company did not meet the minimum $1.00 bid price requirement during the initial compliance period and has expressed its intention to cure the deficiency, potentially through a reverse share split [2][3] - If the closing bid price reaches at least $1.00 for a minimum of 10 consecutive business days before the deadline, the company will regain compliance [4] Company Overview - SciSparc Ltd. is a clinical-stage pharmaceutical company focused on developing therapies for central nervous system disorders and rare diseases [5] - The company is engaged in drug development programs including SCI-110 for Tourette Syndrome and SCI-210 for autism and status epilepticus, utilizing cannabinoid pharmaceuticals [5] - SciSparc also has a controlling interest in a subsidiary that sells hemp seed oil-based products on Amazon [5]

Core Insights - SciSparc Ltd. has entered into a merger agreement with AutoMax Motors Ltd., a leading automotive importer in Israel, which has received its first shipment of vehicles from JAC Motors, a Chinese automotive company [1][4] - The shipment follows regulatory approvals for direct importation, allowing AutoMax to begin marketing and sales activities for JAC Motors vehicles in Israel [2] - JAC Motors focuses on electric vehicles (EVs), aligning with AutoMax's strategy to meet the rising demand for sustainable transportation solutions in the local market [3] Company and Industry Summary - AutoMax Motors has launched direct import and distribution operations for JAC Motors vehicles, marking a significant milestone in its business [1][2] - JAC Motors is recognized for its innovative range of electric vehicles, supported by advanced R&D and battery technologies, positioning it as a pioneer in sustainable transportation [3] - SciSparc has provided financial support to AutoMax, facilitating the transaction with JAC Motors and potentially paving the way for SciSparc's expansion into the automotive sector through the merger [4]

Core Viewpoint - SciSparc Ltd. is expanding its joint venture MitoCareX Bio Ltd. to include research on pancreatic cancer following positive initial in-vitro results, indicating a significant growth in its therapeutic focus [1][2][3]. Company Overview - SciSparc Ltd. is a clinical-stage pharmaceutical company specializing in cannabinoid pharmaceuticals, with ongoing drug development programs targeting conditions such as Tourette Syndrome, Alzheimer's disease, autism, and status epilepticus [6]. Research and Development - MitoCareX has achieved promising results in drug discovery for pancreatic cancer, utilizing a computationally advanced platform that screened millions of small molecules to identify potential anti-cancer treatments [2][3]. - The company is developing a predictive AI model to explore broader chemical spaces, aiming to discover novel anti-cancer compounds targeting the mitochondrial SLC25 protein family [4]. Market Context - Pancreatic cancer is noted as one of the most aggressive cancers, with a 5-year survival rate of only 12% as of 2023, highlighting a significant unmet medical need in this area [5].

On Monday, SciSparc Ltd SPRC stock is trading higher with a session volume of 30.86 million compared to an average volume of 7.73 million as per data from Benzinga Pro.SciSparc announced, as part of its ongoing collaboration with Clearmind Medicine Inc. CMND, the publication of a European patent application submitted by Clearmind under the European Patent Office for combination therapy of MEAI and N-Acylethanolamines for binge behavior, including alcohol consumption, eating, tobacco consumption, shopping, a ...

TEL AVIV, Israel, Jan. 06, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, announced today as part of its ongoing collaboration with Clearmind Medicine Inc. (“Clearmind”) (Nasdaq: CMND) (FSE: CWY0), a biotechnology company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated mental ...

U.S. stocks traded slightly lower toward the end of trading, with the S&P 500 edging lower on Thursday.The Dow traded down 0.03% to 43,283.94 while the NASDAQ fell 0.05% to 20,021.98. The S&P 500 also fell, dropping, 0.07% to 6,035.54.Check This Out: Wall Street’s Most Accurate Analysts Give Their Take On 3 Utilities Stocks With Over 4% Dividend YieldsLeading and Lagging SectorsIndustrials shares rose by 0.3% on Thursday.In trading on Thursday, consumer discretionary shares dipped by 0.5%.Top HeadlineU.S. i ...

TEL AVIV, Israel, Dec. 26, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), announced that AutoMax Motors Ltd., (“AutoMax”), a leading automotive importer and distributor in Israel with which the Company has entered into an agreement and plan of merger, received its first shipment of vehicles manufactured by Anhui Jianghuai Automobile Group Co., Ltd. (“JAC Motors”), a globally recognized Chinese automotive company. This marks a significant milestone in AutoMax’s direct import ...

According to the LOI, SciSparc's pharmaceuticals assets are valued at approximately US$11.6 million TEL AVIV, Israel, Dec. 16, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (NASDAQ:SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today that it had signed an amendment to its non-binding letter of intent (the "LOI") to spin off by reverse merger its advanced clinica ...

Exhibit 99.1 SCISPARC LTD. INTERIM CONSOLIDATED FINANCIAL STATEMENTS AS OF JUNE 30, 2024 UNAUDITED INDEX Page | Consolidated Statements of Financial Position | 2-3 | | --- | --- | | Consolidated Statements of Profit or Loss and Other Comprehensive Loss | 4 | | Consolidated Statements of Changes in Equity (Deficit) | 5-7 | | Consolidated Statements of Cash Flows | 8-10 | | Notes to Interim Consolidated Financial Statements | 11-23 | SCISPARC LTD. CONSOLIDATED STATEMENTS OF FINANCIAL POSITION | | | | June 30, ...

FDA confirms that SciSparc's study may proceed only a month after application submission TEL AVIV, Israel, Sept. 30, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced that the U.S. Food and Drug Administration ("FDA") has confirmed that its investigational new drug ("IND") application for its first in class dru ...